Petauri

Wishing all of our clients, partners, colleagues, and friends a Happy New Year. As we step into 2025, we are excited about the opportunities and innovations that lie ahead. This year, we are committed to pushing the boundaries of what's possible and continuing to bridge the gap between groundbreaking therapies and the complex healthcare ecosystem to ensure that innovative therapies reach the patients who need them most. Cheers to a transformative year ahead! #HealthcareInnovation #MarketAccess #HEOR #HealthEconomics #Medcomms

As we wrap up an incredible year, we want to take a moment to reflect on the partnerships and collaboration that have made 2024 so impactful. This season, we are especially grateful for the talented 400+ people who make up Petauri, our clients who trust in us, and the shared vision that unites us—improving patient outcomes by speeding access to life-changing healthcare innovations. Here’s to a joyful holiday season and a bright year ahead. We can’t wait to see what 2025 will bring. Petauri MAx, Petauri Kinect, FORCE Communications-Powered by Petauri™, Mtech Access, Delta Hat Limited, Bluprint Oncology, Verascity Science, Formulary Insights—Powered by Petauri #HappyHolidays #HealthcareInnovation #MarketAccess #ScientificCommunications #HEOR 

Thanks to the FDA, real-world evidence (RWE) has become even more real. With the launch of the CDER Center for Real-World Evidence Innovation (CCRI) the FDA aims to enhance the use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making. As CDER Director Patrizia Cavazzoni, MD said, the CCRI is a significant step in unlocking RWD's potential to inform clinical decisions. CCRI will promote consistency and transparency in RWD/RWE initiatives across CDER, fostering innovation in drug development. At Petauri, RWE is foundational to many of the value propositions we have developed to overcome barriers to patients receiving life-changing healthcare innovations. Let's discuss how we can put our unique approach to RWE to work for your brand at https://lnkd.in/eadTaaSM #FDA #RealWorldEvidence #RealWorldData #Innovation #Healthcare https://lnkd.in/eQXpkajD

As we wrap up an incredible year, we want to take a moment to reflect on the partnerships and collaboration that have made 2024 so impactful. This season, we are especially grateful for the talented 400+ people who make up Petauri, our clients who trust in us, and the shared vision that unites us—improving patient outcomes by speeding access to life-changing healthcare innovations. Here’s to a joyful holiday season and a bright year ahead. We can’t wait to see what 2025 will bring. Petauri MAx, Petauri Kinect, FORCE Communications-Powered by Petauri™, Mtech Access, Delta Hat Limited, Bluprint Oncology, Verascity Science, Formulary Insights—Powered by Petauri #HappyHolidays #HealthcareInnovation #MarketAccess #ScientificCommunications #HEOR 

As a thought leader in the Real-World Evidence (RWE) space, Petauri presented the poster 'Payer Preferences Around Manufacturer Provided Evidence and Engagements in the US' at ISPOR Europe 2024. The poster represents perspectives from national and regional Managed Care Organizations (MCOs), Pharmacy Benefit Managers (PBMs), and Integrated Delivery Networks (IDNs) in the US. While sentiment regarding information provided by biopharmaceutical manufacturers varies, payers strongly value transparent and high-quality scientific evidence. Both pre- and post-launch, payers continue to be most interested in clinical efficacy and safety data, along with pricing/economic information.    Let's discuss opportunities to build upon these research findings to implement impactful market access and HEOR strategies for your brand. Please contact us at https://lnkd.in/eadTaaSM   Poster Authors: Nicole Lodowski, Bob Nordyke, Benjamin Tindall, Emily Coriale, PharmD, Joe Honcz, Sree Mangala C.   #ManagedCare #ManagedMarkets #HealthcostInsights #ISPOREurope2024 #HealthEconomics #PharmaInsights #RWE #Healthcare

In the poster, 'Insights from an Expert Advisory Board: The Trends Driving Changes in Managed Care', presented at ISPOR Europe 2024, Petauri presents the perspectives of 14 managed care decision-makers (payers). According to nearly all of these managers, over the next 3 years, it’s likely or very likely that high-cost treatments for chronic diseases will increase healthcare costs overall, while biosimilars and generics are anticipated to improve access and affordability. Respondents unanimously agreed that the escalating use of high-cost treatments for chronic diseases will impact their organizations’ cost-management strategies. Let's discuss the implications of our findings and how we can help prepare your business for what's to come. You can reach us at https://lnkd.in/eadTaaSM   Poster Authors: Joe Honcz, Emily Coriale, PharmD, Armin Vazehgoo, Benjamin Tindall   #ManagedCare  #HealthcostInsights  #Biosimilars  #HealthcareAccessibility  #ISPOREurope2024  #HealthEconomics  #PharmaInsights  #PatientAccess  #HealthcareCosts

Join us in celebrating Nicole Lodowski, Managing Director at Petauri Evidence, on being named one of MM+M’s prestigious 40 Under 40 Honorees for 2025! The 40 Under 40 Award spotlights the brightest young minds across the industry and the impact their contributions are making. To learn more about Nicole’s recognition visit: https://lnkd.in/eca6ZVzt. The full list of 2025 honorees can be found here: https://lnkd.in/eHjEsykK. #HEOR #40Under40 #MarketAccess #Leadership #InnovationInHealthcare

From fostering meaningful interactions to delivering innovative solutions, Petauri Advance is here to enhance your scientific engagement strategies and drive powerful connections. · Insights Generation · In-Person Engagement · Booth Design and Content Connect with us at an upcoming conference or reach out directly at www.petauri.com/contact to learn more about how we can support your conference goals. Bluprint Oncology, FORCE Communications-Powered by Petauri™, Verascity Science. #ScientificCommunications #Oncology #Hematology #ScientificStrategy #GI25 #TTLC25 #ASCO

In a recent survey of payers conducted by Petauri, 80% of payers report some use of manufacturer-provided health economic models to inform and calibrate internal models. In a poster presented at ISPOR Europe 2024, Petauri offers insights into payer preferences around manufacturer-provided evidence and engagements in the US. You can reach us at https://lnkd.in/eadTaaSM to discuss what payers value when using modeling services––such as ours––and the implications for your brand. Poster Authors Nicole Lodowski, Bob Nordyke, Benjamin Tindall, Emily Coriale, PharmD, Joe Honcz, and Sree Mangala C. #HEOR #PIEActof2022 #pharma #biotech #drugdevelopment #ManufacturerProvidedHealthEconomicModels

We are thrilled to announce that Megan Jankura has joined Petauri MAx as SVP, Managing Director, and will be co-leading Petauri MAx alongside organization veteran, Liz Lucas. Megan brings nearly two decades of strategic leadership in market access and business development to the organization. Combined with Liz’s expertise in payer engagement strategies, the two will shape the future of Petauri MAx and drive the organization’s vision of improving patient outcomes by speeding access to life-changing healthcare innovations. To learn more visit: https://lnkd.in/dV-a64y7 #MarketAccess #HealthcareInnovation #Pharma #Biotech #Leadership